DE60232963D1 - Oral anzuwendende zuckerkrankheitshemmende "einmal täglich" arzneizusammensetzung enthaltend eine biguanidverbindung und zumindestens einen anderen wirkstoff - Google Patents

Oral anzuwendende zuckerkrankheitshemmende "einmal täglich" arzneizusammensetzung enthaltend eine biguanidverbindung und zumindestens einen anderen wirkstoff

Info

Publication number
DE60232963D1
DE60232963D1 DE60232963T DE60232963T DE60232963D1 DE 60232963 D1 DE60232963 D1 DE 60232963D1 DE 60232963 T DE60232963 T DE 60232963T DE 60232963 T DE60232963 T DE 60232963T DE 60232963 D1 DE60232963 D1 DE 60232963D1
Authority
DE
Germany
Prior art keywords
medicamental
degrad
orange
inhibiting
daily
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60232963T
Other languages
English (en)
Inventor
Catherine Castan
Gerard Soula
Remi Meyrueix
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Flamel Technologies SA
Original Assignee
Flamel Technologies SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flamel Technologies SA filed Critical Flamel Technologies SA
Application granted granted Critical
Publication of DE60232963D1 publication Critical patent/DE60232963D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60232963T 2001-05-23 2002-05-23 Oral anzuwendende zuckerkrankheitshemmende "einmal täglich" arzneizusammensetzung enthaltend eine biguanidverbindung und zumindestens einen anderen wirkstoff Expired - Lifetime DE60232963D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0106854A FR2825023B1 (fr) 2001-05-23 2001-05-23 Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
PCT/FR2002/001745 WO2002094285A1 (fr) 2001-05-23 2002-05-23 Forme pharmaceutique orale antidiabetique 'une prise par jour' comprenant une biguanide et au moins un autre principe actif

Publications (1)

Publication Number Publication Date
DE60232963D1 true DE60232963D1 (de) 2009-08-27

Family

ID=8863626

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60232963T Expired - Lifetime DE60232963D1 (de) 2001-05-23 2002-05-23 Oral anzuwendende zuckerkrankheitshemmende "einmal täglich" arzneizusammensetzung enthaltend eine biguanidverbindung und zumindestens einen anderen wirkstoff

Country Status (10)

Country Link
US (1) US20040219212A1 (de)
EP (1) EP1389118B9 (de)
JP (1) JP4515032B2 (de)
CA (1) CA2447926C (de)
DE (1) DE60232963D1 (de)
ES (1) ES2329555T3 (de)
FR (1) FR2825023B1 (de)
IL (2) IL158506A0 (de)
PT (1) PT1389118E (de)
WO (1) WO2002094285A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
WO2002055009A1 (en) * 2001-01-12 2002-07-18 Sun Pharmaceutical Industries Limited Spaced drug delivery system
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
WO2003061643A1 (es) * 2002-01-25 2003-07-31 Laboratorios Silanes, S.A. De C.V. Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
FR2842735B1 (fr) 2002-07-26 2006-01-06 Flamel Tech Sa Microcapsules a liberation modifiee de principes actifs peu solubles pour l'administration per os
FR2842736B1 (fr) 2002-07-26 2005-07-22 Flamel Tech Sa Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s)
ATE457166T1 (de) * 2003-07-24 2010-02-15 Wockhardt Ltd Orale zusammensetzungen zur behandlung von diabetes
EP1772149A1 (de) * 2004-07-27 2007-04-11 Kowa Company. Ltd. Wirkstoff zur prävention oder behandlung von diabetes
EP1909771A1 (de) * 2005-08-02 2008-04-16 Miv Therapeutics Inc. Mikrovorrichtungen mit nanokapseln für die kontrollierte abgabe von arzneimitteln und herstellungsverfahren dafür
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
AU2006311601A1 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide
US7435741B2 (en) * 2006-05-09 2008-10-14 Teva Pharmaceutical Industries, Ltd. 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
EP2270007A1 (de) * 2006-05-09 2011-01-05 Teva Pharmaceutical Industries Ltd. 2-N-{5-[[4-[2-(Methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedion} Bernsteinsäure, Verfahren zur Herstellung und Zusammensetzungen mit Rosiglitazon Maleat
CN102105140B (zh) * 2008-07-02 2013-10-23 巴斯夫欧洲公司 涂覆片剂的方法
EA029077B1 (ru) * 2010-03-09 2018-02-28 Алкермес Фарма Айэленд Лимитед Устойчивая к спирту фармацевтическая лекарственная форма
GR1007299B (el) * 2010-03-24 2011-06-06 Uni - Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Αβεε Με Δ.Τ. Uni-Pharma Αβεε, Πρωτοτυπη αναβραζουσα φαρμακευτικη συνθεση υδροχλωρικης μετφορμινης με τη μορφη δισκιου
US20120095059A1 (en) * 2010-04-13 2012-04-19 Jorge Luis Rosado Compositions and Methods for Treating Type II Diabetes and Related Disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
KR102231554B1 (ko) * 2012-01-06 2021-03-23 앤지 파마 유에스 엘엘씨 대사 장애를 치료하는 조성물 및 방법
KR20200137035A (ko) 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 바이구아나이드 조성물 및 대사 장애를 치료하는 방법
JP2015512945A (ja) * 2012-04-13 2015-04-30 バナー ファーマキャップス，インコーポレイティド 錠剤と液体または半固体の充填剤とを含む軟質弾性カプセル、ならびにそれらの製造方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079509C (en) * 1991-10-01 2002-05-14 Shigeyuki Takada Prolonged release microparticle preparation and production of the same
FR2725623A1 (fr) * 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
AU3357499A (en) * 1998-03-18 1999-10-11 Peter Schenk Stationary exercise bicycle simulator
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
EP0974356B1 (de) * 1998-07-15 2003-09-24 Merck Sante Tabletten enthaltend eine Kombination von Glibenclamid und Metformin
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
DE19860698A1 (de) * 1998-12-30 2000-07-06 Hexal Ag Neue pharmazeutische Zusammensetzung
US7576131B2 (en) * 1999-06-04 2009-08-18 Metabolex, Inc. Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US6428809B1 (en) * 1999-08-18 2002-08-06 Microdose Technologies, Inc. Metering and packaging of controlled release medication
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
BR0015294A (pt) * 1999-11-03 2003-07-15 Bristol Myers Squibb Co Método para tratamento da diabetes
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
FR2816840B1 (fr) * 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation

Also Published As

Publication number Publication date
PT1389118E (pt) 2009-10-21
US20040219212A1 (en) 2004-11-04
FR2825023A1 (fr) 2002-11-29
JP4515032B2 (ja) 2010-07-28
IL158506A (en) 2012-10-31
WO2002094285A1 (fr) 2002-11-28
IL158506A0 (en) 2004-05-12
EP1389118B1 (de) 2009-07-15
FR2825023B1 (fr) 2005-04-15
EP1389118A1 (de) 2004-02-18
JP2004534768A (ja) 2004-11-18
EP1389118B9 (de) 2009-11-18
CA2447926C (fr) 2010-04-20
ES2329555T3 (es) 2009-11-27
CA2447926A1 (fr) 2002-11-28

Similar Documents

Publication Publication Date Title
DE60232963D1 (de) Oral anzuwendende zuckerkrankheitshemmende "einmal täglich" arzneizusammensetzung enthaltend eine biguanidverbindung und zumindestens einen anderen wirkstoff
IL159086A0 (en) 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
HUP0303825A3 (en) 1h-benzimidazole and 3h-imidazo-[4,5b]pyridine-derivatives, their use and pharmaceutical compositions containing them
HUP0401567A3 (en) Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
DE60226704D1 (de) Acylierte 6,7,8,9-tetrahydro-5h-benzocycloheptenyl-amine und deren pharmazeutische verwendung
DE60121155D1 (de) Synergistische orale zusammensetzung gegen zahnbelag und gingivitis
NO20031407D0 (no) Glukopyranosyloksybenzylbenzen-derivater og medisinske sammensetninger inneholdende det samme
HUP0303325A3 (en) Pharmaceutical salts and pharmaceutical compositions containing them
DE60038455D1 (de) Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
FR2825277B1 (fr) Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd
IL151829A0 (en) Carbamate derivatives and pharmaceutical compositions containing the same
DE60016602D1 (de) Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
AU2003241185A1 (en) Antibacterial flavor and fragrance composition and halitosis-inhibition flavor and fragrance composition and oral care composition containing the same
HUP0402003A3 (en) Substituted 1,4-benzodiazepines, pharmaceutical compositions containing them and uses thereof
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same
DE60310377D1 (de) Lang wirksame, parasiten-abtötende zubereitung enthaltend eine salicylanilid verbindung, eine polymere verbindung und mindestens eine weitere parasiten-abtötende verbindung
DE60045402D1 (de) Silylalkylplatin (IV) Verbindungen und deren Herstellung
DE60210784D1 (de) Orale antidiabetische wirkstoffe
HUP0401403A3 (en) 2,4-diaminothiazole derivatives, their use and pharmaceutical compositions containing them
CY2007011I2 (el) Πολυμορφες ενος κρυσταλλικου κιτρικου αλατος αζαδικυκλο (2,2,2) οκταν -3- αμινης και φαρμακευτικες συνθεσεις τους
IL159006A0 (en) Phenoxy-phenyl derivatives and pharmaceutical compositions containing the same
IL169163A0 (en) Optically active dihydropyridine derivative and pharmaceutical compositions containing the same
HRP20040171A2 (en) Combined preparations, containing 1,4-benzothiepine-1,1-dioxide derivatives and other active substances, and the use thereof
HUP0303593A3 (en) Biguanide derivatives, pharmaceutical compositions containing them and their use
DE60210446D1 (de) Zusammensetzungen enthaltend einen alpha-2-adrenorezeptoragonisten und eine fettsaeure

Legal Events

Date Code Title Description
8364 No opposition during term of opposition